Abstract
Previous studies in this laboratory have demonstrated a delay in the elimination of lipids from the blood stream of hyperlipemic patients after intravenous fat infusion (1). These studies suggested a defect in the lipemia clearing mechanism in hyperlipemia. We subsequently found (2) that the serum of patients with hyperlipemia (primary and secondary to diabetes, nephrosis, glycogen storage disease) inhibited the heparin-induced lipemia clearing activity of normal serum. It was further found that the inhibitory activities of hyperlipemic serum were associated with the supernatant fatty layer obtained after highspeed centrifugation (3). Similar inhibitory activities as in hyperlipemic serum are present in human and other mammalian tissue (4). Since normal human and other mammalian tissue, like hyperlipemic serum, inhibit a number of lipase preparations as well as heparin-induced lipemia clearing activity (5, 6), they can be considered to have general antilipolytic action (7, 8, 9).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
